Table 2.
Biochemical parameters for all patients at baseline (week 0), after the first treatment period (week 2), after washout (week 4) and after the second treatment period (week 6)
| Groupa | Baseline | After the first treatment period | After washout | After the second treatment period | |
|---|---|---|---|---|---|
| calcium (mmol/l) mean ± SD |
1 |
2.33 ± 0.10 |
2.34 ± 0.11 |
2.35 ± 0.08 |
2.33 ± 0.07 |
| |
2 |
2.28 ± 0.07 |
2.30 ± 0.12 |
2.31 ± 0.11 |
2.34 ± 0.11 |
| phosphate (mmol/l) mean ± SD |
1 |
1.08 ± 0.24 |
1.11 ± 0.24 |
1.16 ± 0.20 |
1.11 ± 0.19 |
| |
2 |
1.03 ± 0.21 |
1.01 ± 0.18 |
1.04 ± 0.17 |
1.05 ± 0.19 |
| creatinine (μmol/l) mean ± SD |
1 |
141.1 ± 29.7 |
143.4 ± 27.1 |
138.9 ± 29.1 |
146.6 ± 35.1 |
| |
2 |
156.9 ± 26.8 |
166.2 ± 24.7 |
158.3 ± 21.6 |
169.5 ± 29.6 |
| eGFR (ml/min/1,73 m2) mean ± SD |
1 |
40.1 ± 7.0 |
38.9 ± 6.0 |
40.8 ± 7.7 |
38.9 ± 7.7 |
| |
2 |
36.4 ± 5.0 |
33.8 ± 2.7 |
35.6 ± 3.3 |
33.5 ± 6.3 |
| 25(OH) vitD (nmol/l) mean ± SD |
1 |
99.4 ± 23.7 |
94.9 ± 22.3 |
93.8 ± 26.1 |
86.1 ± 18.0 |
| |
2 |
88.0 ± 22.0 |
86.6 ± 25.6 |
84.4 ± 31.0 |
85.6 ± 30.6 |
| FePO4 (%)b mean ± SD |
1 |
26.8 ± 6.7 |
33.5 ± 9.1 |
31.7 ± 11.6 |
29.3 ± 8.6 |
| |
2 |
34.5 ± 9.5 |
36.3 ± 10.5 |
38.1 ± 12.2 |
41.0 ± 11.7 |
| 1.25(OH)2 vitD (pmol/l) median, range |
1 |
72.0 (23.0-112.0) |
70.0 (29.0-130.0) |
64.0 (32.0-94.0) |
61.0 (32.0-108.0) |
| |
2 |
65.5 (46.0-175.0) |
56.6 (37.0-125.0) |
70.0 (27.0-89.0) |
60.5 (37.0-99.0) |
| FGF23 (pg/ml) mean ± SD |
1 |
90.7 ± 28.4 |
105.8 ± 41.6 |
102.6 ± 33.1 |
79.1 ± 36.5 |
| |
2 |
110.2 ± 73.7 |
127.6 ± 76.6 |
142.3 ± 52.2 |
110.4 ± 41.7 |
| PTH (pg/ml) median, range |
1 |
35.9 (16.3-147.4) |
26.5 (14.6-55.2) |
35.0 (14.3-72.5) |
36.1 (13.4-106.9) |
| |
2 |
35.3 (22.6-73.9) |
38.7 (21.2-61.0) |
33.7 (23.6-63.1) |
37.7 (19.7-71.3) |
| PINP (μg/l) median, range |
1 |
56.5 (23.2-115.6) |
53.0 (24.5-133.8) |
52.8 (30.0-89.7) |
60.8 (28.3-82.2) |
| |
2 |
36.9 (17.1-55.6) |
40.5 (20.3-61.4) |
37.9 (17.5-55.4) |
38.4 (16.8-49.2) |
| Osteocalcin (ng/ml) median, range |
1 |
17.3 (7.6-37.7) |
18.1 (8.9-38.7) |
16.5 (9.4-35.6) |
18.1 (9.6-34.9) |
| |
2 |
12.8 (7.4-25.2) |
13.5 (7.7-28.0) |
13.6 (9.7-24.5) |
13.4 (10.5-26.4) |
| BALP (U/L) median, range |
1 |
24.3 (14.7-43.4) |
22.8 (13.0-37.8) |
25.1 (13.0-39.3) |
27.1 (13.7-41.2) |
| |
2 |
17.9 (12.7-32.0) |
19.7 (10.8-33.0) |
19.2 (9.4-35.1) |
21.3 (11.6-36.6) |
| NTx (nM BCE)c median, range |
1 |
16.8 (10.3-77.0) |
14.4 (10.4-54.8) |
13.6 (10.2-25.6) |
13.9 (11.1-42.2) |
| 2 | 13.2 (5.9-34.3) | 11.9 (7.3-18.3) | 11.8 (6.9-21.4) | 14.1 (8.0-22.1) |
aGroup-1: The alphacalcidol-sevelamer group: alphacalcidol for two weeks (first treatment period) followed by sevelamer carbonate (second treatment period) after two weeks washout (data shown for the nine patients that completed the crossover study).
Group-2: The sevelamer-alphacalcidol group: sevelamer carbonate for two weeks (first treatment period) followed by alphacalcidol (second treatment period) for two weeks after two weeks washout.
bThe treatment difference was statistically significant (p = 0.028).
cnM BCE = nmol Bone Collagen Equivalents.